Moderna
-
healthModerna CEO Warns Europe Is Vulnerable Without mRNA Manufacturing Capacity
Stéphane Bancel cautions that continental Europe lacks industrial mRNA infrastructure, leaving it exposed to future pandemics or bioterrorism, as Moderna shifts strategy toward cancer vaccines.
-
healthRSV Vaccine: Who Needs It and Why?
Essential facts about the RSV vaccine, including who should get it, timing, side effects, and benefits for older adults and pregnant women.
-
healthNew mRNA Vaccine Combo Slashes Melanoma Recurrence Risk by 49%
Merck-Moderna personalized mRNA cancer vaccine plus KEYTRUDA reduces melanoma recurrence or death risk over five years.
-
healthWHO Slashes Congo Ebola Count to 116; Vaccine Race Intensifies
WHO drastically revises suspected Ebola cases in Congo down to 116, from over 1,000, as testing clarifies other diseases. Five patients recover.
-
healthmRNA Vaccine Slashes Melanoma Recurrence Risk in Landmark Trial
A new mRNA cancer therapy from Merck and Moderna cuts melanoma recurrence or death risk by 49% over five years, offering new hope for late-stage patients.
-
healthCEPI Grants $61.8 Million to Accelerate Ebola Vaccine Development
CEPI awards $61.8M to Moderna, Oxford, and IAVI for rapid development of vaccines against the Bundibugyo Ebola strain.
-
healthModerna Receives $50 Million to Develop mRNA Ebola Vaccine
CEPI funds Moderna, IAVI, and Oxford to develop vaccines against the deadly Bundibugyo Ebola strain currently raging in the DRC.
-
healthRush to Develop Ebola Vaccines as Deadly Outbreak Spreads
The Bundibugyo Ebola species has killed nearly 250 people. Three vaccines are in development as fears grow of a major epidemic.